Moderna (NASDAQ:MRNA) executives highlighted progress on cost reductions, a ramp in international partnerships, and multiple late-stage pipeline milestones during the company’s fourth-quarter 2025 ...
Thank you, Kevin. Good morning, everyone, and thank you for joining us on today’s call to discuss Moderna, Inc.’s fourth quarter 2025 financial results and business update. On today’s call are ...
When HHS overhauled the CDC’s childhood immunization schedule in January, it significantly reduced the number of vaccines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results